Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2893|25|1|4-9

ISSN： 1352-0504

Source： JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol.25, Iss.1, 2018-01, pp. : 4-9

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy of regimens combining direct acting antiviral agents for hepatitis C virus recombinant form RF1_2k/1b

By  

HEPATOLOGY RESEARCH, Vol. 48, Iss. 1, 2018-01 ,pp. : 3-4

John Wiley & Sons Inc

Access to resources Recommend Favorite

Will IL28B polymorphism remain relevant in the era of direct‐acting antiviral agents for hepatitis C virus?

By  

HEPATOLOGY, Vol. 56, Iss. 1, 2012-07 ,pp. : 373-381

John Wiley & Sons Inc

Access to resources Recommend Favorite

Chronic hepatitis caused by hepatitis C virus showing a discrepancy between serogroup and genotype because of intergenotypic 2b/1b recombination: A pitfall in antiviral therapy with direct‐acting antivirals

By  

HEPATOLOGY RESEARCH, Vol. 48, Iss. 3, 2018-02 ,pp. : E372-E378

John Wiley & Sons Inc

Access to resources Recommend Favorite

Interferon‐free, direct‐acting antiviral therapy for chronic hepatitis C

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 1352-0504, Iss. 11, 2015-11 ,pp. : 861-870

John Wiley & Sons Inc

Access to resources Recommend Favorite

Interferon‐free, direct‐acting antiviral therapy for chronic hepatitis C

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. 11, 2015-11 ,pp. : 861-870

John Wiley & Sons Inc

Access to resources Recommend Favorite